Jiuzhou Pharmaceutical: Received the Approval Notice for the Application of Marketization of Cyproterone Acetate Chemical Raw Materials

Jiuzhou Pharmaceuticals announced that it has recently received the "Chemical Raw Material Drug Market Approval Notification" issued by the National Medical Products Administration for levonorgestrel. This raw material drug is an anti-anxiety drug. The company submitted the application for market approval in July 2024 and has invested approximately 6.23 million yuan in research and development. The global market sales in 2024 reached 390 million US dollars, and it is expected to reach 750 million US dollars by 2031. This approval will enrich the company's product structure and enhance its competitiveness, but it will not have a significant impact on performance in the short term. Additionally, there are uncertainties in drug production and sales.